Johnson & Johnson has listed four prescription drugs on TrumpRx, the government-run discount platform President Trump launched earlier this year, according to a Reuters report published in May 2026. The move makes J&J one of the highest-profile pharmaceutical companies to participate in the administration’s drug-pricing initiative, which lets patients compare retail prices against negotiated discounts on a federal .gov website.
Two of the four drugs can be confirmed through dedicated product pages on the platform: Xarelto, a widely prescribed blood thinner used to prevent strokes and treat blood clots, and Invokamet, a combination medication for type 2 diabetes. Both pages carry a “from Johnson & Johnson” label and route patients to J&J Direct, the company’s own fulfillment channel, for ordering and delivery. Reuters reported that two additional J&J drugs are also listed, but their identities have not been independently confirmed through product pages or official J&J statements. The TrumpRx browse catalog lists all available medications, and additional J&J products appear there, though individual product-page verification for each has not been completed.
How the platform works
TrumpRx does not operate like a pharmacy. Instead, it functions as a government-hosted referral hub. Each product page displays an “Original Price,” a “TrumpRx Price,” and a percentage discount. When a patient decides to purchase, the site directs them to the drugmaker’s own direct-to-consumer channel and provides a coupon. The government serves as the storefront; the manufacturer handles fulfillment.
For J&J, that means patients ordering Xarelto or Invokamet through TrumpRx are routed to J&J Direct, which includes a dedicated support phone number and posted operating hours. The arrangement effectively bypasses traditional pharmacy benefit managers and retail pharmacy chains for those transactions, creating a direct pipeline between the company and consumers.
A White House announcement accompanying the platform’s launch stated that TrumpRx debuted with more than 40 medications, including GLP-1 drugs for weight loss and diabetes. The announcement described the pricing framework as built on “Most-Favored-Nation” agreements with drugmakers and said additional medications would be added on a rolling basis. The administration framed the platform as delivering “massive, immediate savings to millions of Americans.” Those characterizations come from the White House itself and should be read as advocacy rather than an independent audit of patient cost reductions.
What the discounts actually look like
Both the Xarelto and Invokamet product pages show percent-off figures alongside original and discounted prices, but neither the platform nor J&J has published the methodology behind those numbers. It is unclear whether the discounts reflect reductions from wholesale acquisition cost, pass-throughs of existing rebates, or entirely new pricing tiers negotiated specifically for TrumpRx. Without that transparency, it is difficult to judge how the posted prices compare with what patients already receive through insurance plans, pharmacy discount cards, or J&J’s own existing patient assistance programs.
Xarelto and Invokamet are both brand-name drugs with significant retail price tags, which makes them natural candidates for a platform designed to highlight dramatic percentage savings. Xarelto is among the most widely prescribed anticoagulants in the United States, and Invokamet combines two active ingredients (canagliflozin and metformin) to manage blood sugar. Patients paying out of pocket or facing high copays stand to benefit most from any meaningful reduction, but those with commercial insurance, Medicare Part D, or Medicaid may find the math more complicated.
Key questions that remain unanswered
J&J has not commented publicly. As of May 2026, the company has not issued a press release or public statement detailing whether its TrumpRx participation is a pilot program, a permanent pricing strategy, or a limited-time promotion coordinated with the administration. No official timeline or minimum participation commitment from any manufacturer has been published, and it is unclear whether companies can withdraw products or adjust prices upward with little notice.
Insurance interactions are uncertain. Patients using manufacturer coupons sometimes run into limits on applying those discounts toward deductibles or out-of-pocket maximums, particularly when insurers use copay accumulator programs. The TrumpRx site does not spell out how its coupons interact with existing coverage, formulary rules, or out-of-network restrictions. These are common friction points in manufacturer coupon programs broadly, but no insurer, government official, or benefits expert has publicly addressed how they apply to TrumpRx specifically.
Privacy protections have not been detailed. Because TrumpRx routes patients to company-run portals, questions arise about what information the government retains about user searches and what data manufacturers receive about individuals referred from the federal site. No comprehensive, publicly accessible privacy framework has been released covering data flows among the government, drugmakers, and any third-party processors involved in fulfillment. Neither the White House nor J&J has addressed these questions in public statements as of May 2026.
What patients prescribed Xarelto or Invokamet should know
Anyone currently taking Xarelto or Invokamet can visit the TrumpRx product pages to compare the listed discount against what they pay at their usual pharmacy. The listings include contact information for J&J Direct support, providing a concrete starting point for patients considering the switch to manufacturer fulfillment.
Before making any changes, patients should confirm with their prescribing physician that switching dispensing channels will not disrupt monitoring, prior authorizations, or access to alternative therapies. They should also check with their insurer whether TrumpRx purchases count toward deductibles and out-of-pocket maximums, and whether using the manufacturer’s direct channel could trigger out-of-network penalties.
Until more is known about the durability of these discounts and the terms underlying them, the practical move is to treat TrumpRx as one more price-comparison tool rather than an automatic best deal. Cross-check the posted prices against existing coverage, ask about shipping costs and refill logistics, and document any changes in cost or access over time.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
